Skip to main content

Incidence Rate of Severe Uterine Bleeding Among New Users of Oral Anticoagulants: A Descriptive Analysis

    Basic Details
    Date Posted
    Status
    Complete
    Medical Product
    apixaban
    dabigatran
    oral anticoagulant
    rivaroxaban
    warfarin
    Health Outcome(s)
    severe uterine bleed
    Description

    The goal of this query was to investigate the incidence rate of serious uterine bleeding (SUB) among new users of oral anticoagulants (rivaroxaban, apixaban, dabigatran, and warfarin) in preparation for a risk assessment amongst warfarin and novel oral anticoagulants (NOACs) in the Sentinel Distributed Database (SDD).

    The study period includes data from October 19, 2010 to September 30, 2015. We distributed this request to 16 Data Partners on October 11, 2017.

    Additional Details
    FDA Center
    CDER
    Time Period
    October 19, 2010 - September 30, 2015
    Analysis Type
    Descriptive
    Population / Cohort
    All females
    Data Sources
    Sentinel Distributed Database (SDD)